Following the success of the world’s leading AI Breast Care system, Transpara, now in use across the US and in 30 countries worldwide, ScreenPoint Medical, the company that developed Transpara, has appointed Mark Koeniguer as its new CEO to lead the next phase of growth and accelerate the company’s international expansion.
Koeniguer, who has extensive experience leading and growing transformational technology companies, takes over the helm on 21st February from ScreenPoint Medical’s founder, Professor Nico Karssemeijer, who stays in the company as Chief Scientific Officer.
Mark Koeniguer has over 25 years of healthcare industry experience launching innovative products and leading high-performance teams in domestic and international markets. He has been instrumental in launching and scaling many industry-first technologies including the first Computer Aided Detection algorithm for the early detection of breast cancer, the first mammography analytics platform and a multi-point risk stratified breast screening scorecard.
Recommended AI News: Findora Launches “Prism” to Bridge Native and Smart Chain Assets for Increased DeFi Functionality
“I am delighted to be joining ScreenPoint Medical as we see Transpara AI leading the transformation of the earlier detection of breast cancers at a time when the incidence of the disease is increasing exponentially worldwide,” said Koeniguer.
“I am thrilled to be part of such an impressive team of scientists, researchers and developers focused on early breast cancer detection, prediction and diagnosis. AI has matured since the early 2000s, and is now poised to be a leading clinical decision support tool, assisting radiologists and other clinicians in the global fight to improve cancer survival rates.”
Recommended AI News: Deci’s New Family of Models Delivers Breakthrough Deep Learning Performance on CPU
Prior to his serial entrepreneurial ventures, Mark held various executive leadership positions in Finance, Operations, Sales and Marketing for GE Healthcare. He holds a finance degree from the University of Iowa, and an MBA from the University of Wisconsin, Madison.
Professor Nico Karssemeijer who formed ScreenPoint Medical together with Professor Sir Michael Brady of MIT and Oxford University in 2014, said his focus will be on studies with clinical partners and AI research to support product development. “AI is transforming healthcare and the possibilities for improving accurate and early detection of disease are huge. I’m excited to work with Mark managing the next phase in the growth of ScreenPoint Medical and strengthening our position as leading provider of breast AI solutions.”
Recommended AI News: gStore Puts the Future of Stores in an App
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.